Key result
Monomeric C-reactive protein concentrations ≥5.2 µg/l were associated with a significantly higher risk of asymptomatic carotid atherosclerosis progression (OR 5.5; 95% CI 2.1-14.6; p=0.001).
Why the study?
To examine the relationship between monomeric C-reactive protein (mCRP) and the progression of asymptomatic carotid atherosclerosis in patients at moderate cardiovascular risk by the SCORE model.
Does monomeric C-reactive protein (mCRP) level predict the progression of asymptomatic carotid atherosclerosis in moderate-risk patients on statin therapy?
Cohort (n=80)
Does monomeric C-reactive protein (mCRP) level predict the progression of asymptomatic carotid atherosclerosis in moderate-risk patients on statin therapy?
Elevated monomeric C-reactive protein (mCRP) is a significant predictor of carotid atherosclerosis progression in moderate-risk patients achieving LDL-C targets on statin therapy, outperforming high-sensitivity CRP.
Elevated mCRP associates with carotid plaque progression in moderate-SCORE patients on target LDL-C; leaves open its value as residual risk marker pending validation.
Aim To study the relationship between monomeric C-reactive protein (mCRP) and the progression of asymptomatic carotid atherosclerosis in patients with a moderate risk for cardiovascular diseases (CVD) as assessed with the SCORE model.Material and methods The study included 80 men and women aged 53.1±5.8 years assigned to the category of a moderate risk for CVDs by the SCORE model with a low-density lipoprotein cholesterol (LDL-C) level of 2.7-4.8 mmol/l and asymptomatic, hemodynamically insignificant (<50% luminal narrowing) carotid atherosclerosis according to ultrasonic data. All patients were prescribed atorvastatin to achieve a LDL-C level <2.6 mmol/l. After 7 years of follow-up, ultrasonic examination of carotid arteries was performed, and concentrations of high-sensitivity C-reactive protein (hsCRP) and mCRP were measured.Results A concentration of LDL-C <2.6 mmol/l was achieved in all patients. The progression of atherosclerosis as determined by an increased number of atherosclerotic plaques (ASPs), was observed in 45 (56 %) patients. At 7 months of follow-up, concentrations of cCRP were higher in the group of patients with progressive carotid atherosclerosis, while the levels of hsCRP did not differ between the groups. Increased mCRP concentrations were associated with changes in variables of the "atherosclerotic load", including the number of ASPs, total ASP height, and the intima-media thickness (IMT). In patients with a median mCRP concentration of 5.2 [3.3; 7.1] µg/l and more, the increases in mean ACP number and total ASP height were considerably higher than in patients with mCRP concentrations lower than the median (3.9 and 2.7 times, respectively), whereas the odds ratio for the progression of asymptomatic carotid atherosclerosis was 5.5 (95 % confidence interval, CI: 2.1-14.6; p=0.001). ROC analysis showed that the concentration of hsCRP had no predictive value for prognosis of asymptomatic carotid atherosclerosis (p=0.16), while the area under the ROC curve (AUC) for mCRP was 0.75±0.056 (95 % CI: 0.64-0.86; p=0.001).Conclusion According to the results of 7-year follow-up, the plasma concentration of mCRP was significantly higher in patients with an increased number of ASPs than in patients without this increase. An increased level of mCRP may indicate a higher inflammatory risk of CVD.
No takes yet. Share an insight, caveat, or question.
Melnikov et al. (2022) conducted a cohort in Asymptomatic carotid atherosclerosis (n=80). Monomeric C-reactive protein (mCRP) ≥5.2 µg/l vs. mCRP <5.2 µg/l was evaluated on Progression of asymptomatic carotid atherosclerosis (OR 5.5, 95% CI 2.1-14.6, p=0.001). Monomeric C-reactive protein concentrations ≥5.2 µg/l were associated with a significantly higher risk of asymptomatic carotid atherosclerosis progression (OR 5.5; 95% CI 2.1-14.6; p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: